{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-076085","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.180268+00:00","generated_at":"2026-05-17T13:07:17.485561+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adial reports FDA agreement on Phase 3 design for AD04; Q2 net loss $2.0M, cash $5.9M","bullets":["Completed End of Phase 2 meeting with FDA; agreement on key Phase 3 protocol elements for AD04 in Alcohol Use Disorder.","Cash and equivalents $5.9M as of June 30, 2025 (up from $2.4M at March 31); cash runway into Q2 2026.","Public offering closed June 17, 2025 raised net proceeds ~$3.0M from 11.1M shares and warrants at $0.3251.","Entered manufacturing agreements with Thermo Fisher Scientific and Cambrex for AD04 drug product and substance.","Regained Nasdaq compliance on July 14, 2025 for minimum stockholders' equity of $2.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-076085","json":"https://secwatch.observer/filing/0001213900-25-076085.json","markdown":"https://secwatch.observer/filing/0001213900-25-076085.md","text":"https://secwatch.observer/filing/0001213900-25-076085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/0001213900-25-076085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390025076085/ea0252930-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:07:17.485561+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}